Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Synthetic recombinant protein formed by a sequence of amino acids that are identical to Human Tissue Plasminogen Activator (t-PA) which is found in colostrum and mature milk (Heegaard 1997, Marshall 1986). It is used in the emergency treatment of myocardial infarction, ischemic stroke, and pulmonary emboli. Intravenous administration.
At the date of the last update we did not find any published data on its excretion in breast milk.
Its rapid metabolism (elimination half-life of 5 minutes) and very high molecular weight make its excretion in breast milk unlikely.
Even more, its low oral bioavailability makes it difficult for it to pass into the infant's plasma from ingested breast milk since, due to its protein nature, it is degraded in the gastrointestinal tractand is not absorbed.